Carla A. Frederick MD

Carla Frederick

Carla A. Frederick
MD

Associate Professor

Department of Medicine

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Pulmonary & Critical Care Medicine

Contact Information
UBMD - CF Center of WNY
Cystic Fibrosis Therapeutics Development Center of WNY
Conventus Outpatient Building
1001 Main Street, 4th & 5th floors
Buffalo, NY 14203
(716) 323-0110

Buffalo General Hospital
Department of Pulmonary Medicine
100 High St. B-8
(716) 859-2271
Buffalo, New York 14203
Phone: (716) 323-0110/859-2271
ckinyon@buffalo.edu


Patient Care

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD


Professional Summary:

My clinical practice focuses on management of general pulmonary disease with a specialized interest in cystic fibrosis (CF) and bronchiectasis.

As a physician-consultant for the inpatient UBMD pulmonary consult services at Buffalo General Medical Center (BGMC) and at Roswell Park Cancer Institute, I attend to the needs of hospitalized patients with pulmonary problems in conjunction with the UBMD pulmonary team. This talented inpatient consult team of fellows, residents and medical students works under my supervision, and through my mentoring and teaching of them I hope to share my expertise and give back to medical education by training future healthcare professionals.

I see patients to evaluate and treat pulmonary disorders such as shortness of breath, lung masses, abnormal chest imaging, abnormal pulmonary function tests, chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease and bronchiectasis. My outpatient office locations are the Heart and Lung Center at BGMC and the UBMD Specialty Clinic on Youngs Rd in Williamsville.

As the Adult Director of the Cystic Fibrosis Center in Buffalo, the only care facility in Western New York accredited by the national Cystic Fibrosis Foundation, I provide comprehensive care for individuals with cystic fibrosis with a specially devoted multidisciplinary team. I also provide local care for patients who have received lung transplants for cystic fibrosis, coordinating and collaborating on their care with the transplant physicians and health care providers.

In addition to these responsibilities as a pulmonologist, I attend to hospitalized patients at BGMC and WCHOB who are patients of the UBMD Internal Medicine and Pediatric practices to provide continuity of care for those physicians and their patients.

I am actively engaged in clinical research through many international clinical trials, and through this work strive for improved therapies and a cure for individuals with cystic fibrosis. I am excited to see the major advances made recently with genetic mutation specific therapy being delivered to individuals with CF. Research will continue to progress as a result of successful clinical trials made possible by generous patients and the concerted efforts our highly productive local research team and the Cystic Fibrosis Foundation.

Education and Training:

  • Fellowship, Pulmonary Medicine, University at Buffalo (2011)
  • Fellowship, Pulmonary Medicine, University of Alabama at Birmingham (2010)
  • Residency, Internal Medicine & Pediatrics, University of Tennessee Health Science Center (2009)
  • Residency, Internal Medicine & Pediatrics, University at Buffalo (2007)
  • MD, University at Buffalo (2005)
  • BA, Major: Biology; Minor: Chemistry, Sports Medicine, Case Western Reserve University, Cleveland, OH Magna cum Laude, Magna Cum Laude (2001)

Employment:

  • Adult Program Director, Oshei Women & Children‘s Hospital of Buffalo Lung & CF Center (2012-present)
  • Clinical Assistant Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences

Awards and Honors:

  • CF Excellence in Care Award (2016)
  • Gold Humanism Honor Society (2014)
  • Best Post-Doctoral Presentation Award (2010)
  • Expertise in areas outside of medicine (2005)
  • Class Speaker (2005)
  • Generalist Scholar - Early Match Residency Award (2004)

Research Expertise:

  • Cystic Fibrosis: Director of Adult Cystic Fibrosis Center Co-Principal Investigator of Center for Therapeutic Drug Network at the Women & Children‘s Hospital of Buffalo
  • New therapeutics in cystic fibrosis: Clinical care, clinical research, and translational research related to cystic fibrosis

Grants and Sponsored Research:

  • September 2020–August 2021
    Impact of Advanced Therapy on Mental Health in Cystic Fibrosis (CF)
    University at Buffalo Office of Research and Economic Development
    Role: Co-Investigator
    $25,000
  • August 2014–July 2018
    Success with Therapies Research Consortium
    Cystic Fibrosis Foundation
    Role: Principal Investigator
    $108,000
  • January 2013–May 2015
    AquADEKs-2 trial: a study of the effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in CF.
    Cystic Fibrosis Foundation
    Role: Co-Investigator
  • January 2013–July 2014
    A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy and in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F50
    Vertex Pharmaceuticals, Inc.
    Role: Principal Investigator
  • January 2013–January 2014
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa
    Gilead
    Role: Principal Investigator
  • January 2010–January 2013
    iCARE: I Change Expectations and Raise Adherence
    Cystic Fibrosis Foundation/Genentech, Inc./Novartis Pharmaceuticals Corporation
    Role: Co-Investigator
  • January 2011–December 2012
    VX-770 Expanded Access Program (EAP).
    Vertex Pharmaceuticals, Inc.
    Role: Co-Investigator
  • –December 2012
    Remnant Biological and Autopsy Specimens for Cystic Fibrosis Cell Line Development: New Reagents for Understanding and Overcoming the deltaF508 Mutation.
    Cystic Fibrosis Foundation Therapeutics; UAB Center for Clinical and Translational Science
    Role: Co-Investigator
  • –December 2012
    G551D Observational Study (GOAL) Gastrointestinal pH sub-study.
    Cystic Fibrosis Foundation
    Role: Co-Investigator
  • January 2010–January 2012
    An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis
    Vertex Pharmaceuticals, Inc.
    Role: Co-Investigator
  • –December 2011
    Nasal Potential Difference (NPD) Measurements Remote Reading Services for Multi-Center Trial Entitled: Nasal Potential Studies Utilizing CFTR Modulators.
    UAB Center for Clinical and Translational Science
    Role: Co-Investigator
  • November 2016
    Therapeutics Development Center (TDC)
    Cystic Fibrosis Foundation Therapeutics, Inc.
    Role: Principal Investigator
    $1,820,000
  • January 2015
    A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 6 Years and Older with with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
    Vertex Pharmaceuticals
    Role: Co-Principal Investigator
    $113,215
  • February 2012
    G551D Observational Study (GOAL)
    Cystic Fibrosis Foundation
    Role: Principal Investigator
  • January 2012
    A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors.
    A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients
    Role: Principal Investigator
  • January 2010
    A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone and in Combination with VX-770 in Subjects with Cystic Fibrosis, Homozyg
    Vertex Pharmaceuticals
    Role: Co-Investigator
  • January 2010
    Microbiology of Cystic Fibrosis Sputum.
    Cystic Fibrosis Foundation
    Role: Co-Investigator
See all (7 more)

Journal Articles:

  • Fusco NM, Meaney CJ, Frederick CA, Prescott WA. (2020) Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. Ann Pharmacother (Mar), 54(3): 197-204.
  • Fusco NM, Meaney CJ, Frederick CA, Prescott WA. (2019) Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. Ann Pharmacother (Oct)1060028019-1060028019.
  • Jiang K, Poppenberg KE, Wong L, Chen Y, Borowitz DS, Goetz DM, Sheehan DW, Frederick CA, Tutino VM, Meng H, Jarvis JN. (2019) RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations. J Cyst Fibros (Mar), 18(2): 194-202.
  • Fusco NM, Wells, C., Meancey CJ., Frederick CA., Prescott WA Jr. (2019) Vancomycin vs. vancomycin-rifampin for the treatment of MRSA-associated acute pulmonary exacerbations of cystic fibrosis. J Pediatr Pharmasol and ther. 2018;23(2):125-131 (doi: 10.5863/1551-6776-23.2.125) Contributing author providing medical expertise, clinical context and patient data for research condust. (Mar)
  • Beth A. Smith, Caroline Pardee, Lynne Fries, Christopher Barrick, Nicole Shea and Carla Frederick. (2019) Implications of Substance Use in Patients with Cystic Fibrosis. A. Review. JJ Addie Ther 2019,6(1):037 Senior author writing portions and editing all article text. (Jan)
  • Fusco NM, Meaney CJ, Wells C, Frederick CA, Prescott WA. (2018) Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. J Pediatr Pharmacol Ther (Mar), 23(2): 125-131.
  • Fusco NM, Francisconi R, Meaney CJ, Duman D, Frederick CA, Prescott WA. (2017) Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis. J Pediatric Infect Dis Soc (Sep), 6(3): 103-108.
  • Nicholas M. Fussco, Richard Francisconi, Calvin J. Meaney, Desiree Duman, Carla A. Frederick, William A. Prescott. (2017) Association of Vancomycin Trough Concentration with Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis, Journal of the Pediatric Infectious Diseases. Society.2017;6(3):e103-108 (dio.org/10.1093/jpids/pix043) Contributing author providing medical expertise, clinical context and patients data for research conduct. (May)
  • Jiang, Kaiyu et al. (2017) RNA-Seq from human neutrophils from patients with cystic fibrosis reveals distinct transcriptional differences before and after therapy for pulmonary exacerbations. SREP-16-24674A. Nature 2017 Contributing author providing medical context and patient specimens for research conduct. (Feb)
  • Provost K, Frederick CA, Sethi S. (2017) Bacterial infection. Acute Exacerbations of Pulmonary Diseases (ERS Monograph), European Respiratory Society (Jan).
  • Gelfond, et al. (2017) Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients with Cystic Fibrosis and the G551D mutation. Clin Trans Gastroenterol 2017,8(3):e81 Contributing author providing medical expertise, clinical context and research subject data for research conduct. (Jan)
  • Frederick C, Frederick CA. (2016) Psychosocial Challenges/Transition to Adulthood. Pediatr Clin North Am (Jan), 63(4): 735-749.
  • Goetz DM, Frederick CA, Roach CM, Cogswell A, Smith BA. (2015) The Relationship Between Depression and Patient Outcomes in Children and Adults with CF. Pediatr Pulmonol (Oct), 50(S41): 442-443.
  • Singh S, Frederick CA, Borowitz DS. (2015) Using Video Conferencing for Parent and Patient Advisory Group in Era of Infection Control. Pediatr Pulmonol (Oct), 50(S41): 451-451.
  • Wainwright, CE et al. (2015) Lumacaflor-Ivacaftor in Patients with Cystic Fibrosis. N Enl J Med. 2015 Jul 16;373(3):220-31 Contributing author providing local research subject tolerance investigational product. (Jan)
  • Frederick CA, Goetz DM, Borowitz DS, Surace B. (2014) Patient and Family Perceptions of the New Infection Prevention and Control Guidelines. Pediatr Pulmonol (Sep), 49(S38): 340-340.
  • Prentice S, Goetz DM, Flattery-Walsh L, Frederick CA. (2014) Annual Assessment of Vest Fitting and Condition in Patients Using High-Frequency Chest Wall Oscillation for Airway Clearance. Pediatr Pulmonol (Sep), 49(S38): 400-401.
  • Zahra M, Frederick CA, Thomas R, Borowitz DS. (2014) Gastrografin enemas for treatment of distal intestinal obstruction syndrome in children and adults with cystic fibrosis. J Pharm Nutr Sci (Apr), 4: 76-80.
  • Sabbatini GM, Frederick C, Konstan MW et al. (2011) Nasal potential difference studies utilizing the CFTR modulator quercetin. Pediatr Pulmonol (Jan), 34(300)
  • Solomon GM, Frederick C, Sabbatini G et al. (2010) IP-10 is a potential biomarker of acute pulmonary exacerbations in nasal lavage. Pediatr Pulmonol (Jan), 33(256)
  • Bandi, V., Jakubowyck, M., Kinyon, C. (2003) Infectious Exacerbations of Chronic Pulmonary Disease Associated with Respiratory Viruses and Nontypeable Haemophilus influenzae. FEMS Immunology and Medical Microbiology (Jan)67-75.
See all (11 more)

Abstracts:

  • Frederick CA, Goetz DM, Fries LM, Shea N, Roach C, Smith BA. (2019) Association of Depression with Adverse Health Outcomes in Individuals with CF. (Oct) S391-S391
  • Shea N, Frederick CA, Fries LM, Goetz DM, Roach C, Smith BA. (2019) Mental Health Screening in Cystic Fibrosis: Trajectory to Follow-Up Care. (Oct) S409-S409
  • Smith BA, Roach C, Goetz DM, Shea N, Frederick CA. (2019) The Course of Depression in Cystic Fibrosis: Results of a 6-Year Longitudinal Study. (Oct) S405-S405
  • Frederick CA, Fries LM, Goetz DM, Roach C, Cogswell A, Smith BA. (2018) Relationships Between Depression and Health Outcomes and Trends Over 5 Years of Screening Individuals with CF. (Sep) 423-423
  • Smith BA, Goetz DM, Frederick CA, Roach C, Cogswell A. (2018) Depression and Cystic Fibrosis: Results of a 5-Year Longitudinal Study. (Sep) 429-429
  • Frederick CA, Fries LM, Roach C, Cogswell A, Goetz DM, Smith BA. (2018) Association of CFTR Modulation Therapy Prescription and Mental Health Changes in Individuals with CF. (Sep) 423-423
  • Frederick CA, Goetz DM, Fries LM, Roach C, Cogswell A, Smith BA. (2017) Association of Depression and Adverse Health Outcomes and Trends Over Time in Individuals with CF. (Sep) S500-S500
  • Goetz DM, Frederick CA, Cogswell A, Roach C, Fries LM, Pardee C, Borowitz DS, Smith BA. (2017) Developing and Sustaining a Model for Depression and Anxiety Screening and Stepped Care Treatment: Year Four of the Buffalo Quality Improvement Initiative. (Sep) S416-S416
  • Fusco NM, Francisconi R, Meaney CJ, Duman D, Frederick CA, Prescott WA Jr. (2017) Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. (May) 129-130
  • Gelfond D, Borowitz DS, Frederick CA, Uluer A, Sicilian L, Konstan MW, Rowe SM. (2013) Impact of Ivacaftor Therapy on the Intestinal pH Profile in CF Subjects with the G551D Mutation. (Sep) 405-405
  • Frederick CA, Valvo LE, Borowitz DS. (2012) Assessing Parent Readiness for Transition from a Pediatric to an Adult CF Program. (Sep) 391-391
  • Coburm-Miller C, Frederick CA, Borowitz DS. (2012) Using the New Vitamin D Recommendations to Improve Vitamin D Status in Patients with CF. (Sep) 405-405
  • Penmatsa H, Frederick CA, Nekkalapu S, Conoley VG, Zhang W, Li C, Kappes J, Stokes DC, Naren AP. (2009) Molecular characterization of S1118F-CFTR: A Mutation Associated with Meconium Ileus, Pancreatic Sufficiency, and Intermediate Sweat Chloride Levels. (Oct) 1003-1009
  • Kinyon, C., Cronin, J., Aronica, M. A. (2005) dequacy of Bone Mineral Density Monitoring and Treatment in Adult Cystic Fibrosis Patients in an Adult CF Lung Center. Abstracts of the 8th Annual Resident Scholarly Exchange Day, Buffalo, NY. (Apr)
  • Hiltke, T.J., Kinyon, C. (2000) Differential location of P2 gene in Haemophilus Influenzae Rd and Nontypeable H. influenzae. Abstracts of the 100th Annual Meeting of the American Society fr Microbiology, Los Angeles, CA. (May)
See all (5 more)

Professional Memberships:

  • American College of Chest Physicians (2011–present)
  • American Thoracic Society (2011–present)
  • Christian Medical and Dental Association (2001–present)

Presentations:

  • "Success with Research Therapies Consortium: Community Input Project Symposium Presentation" North American Cystic Fibrosis Conference - Nashville, TN (2019)
  • "Cystic Fibrosis" Pulmonary Faculty and Fellow Conference (2019)
  • "Depression and CF: A 4 Year Longitudinal Study Workshop Presentation" North American Cystic Fibrosis Conference - Indianapolis, IN (2019)
  • "Advance in Cystic Fibrosis" city Wide Grand Rounds (2018)
  • "Cystic Fibrosis" City Wide Resident Lecture (2017)
  • "WNY Society of Health-System Pharmacists continuing Education" Cystic Fibrosis: Connecting the Worlds of Medicine and Pharmacy to Effectively Treat this Disease (2017)
  • "Connection the Worlds of Medicine and Pharmacy to Effectively Treat this Disease" WNY Society of Health-System Pharmacists Continuing Education Cystic Fibrosis (2017)
  • "Evaluation and Management of Incidental Pulmonary Nodules" UBMD Primary Care Update; UBMD (2017)
  • "Opening Conversations About Sustaining Daily CF Care" North American Cystic Fibrosis Conference (2016)
  • "Successful Strategies for Screening for Depression in CF" Memphis Family Day; University of Tennessee Health Science Center (2016)
  • "Cystic Fibrosis" Pulmonary Faculty and Fellow Conference (2016)
  • "Opening Conversations About Sustaining Daily CF Care Workshop Presentation" North American Cystic Fibrosis Conference (2016)
  • "Cystic Fibrosis" Pulmonary Faculty and Fellow Conference (2015)
  • "Adult Patient with Accelerated Pulmonary Decline" North American Cystic Fibrosis Conference; Cystic Fibrosis Foundation; Caregivers Session (2014)
  • "Caregivers Session - Case Presentation and Discussion" North America Cystic Fibrosis Conference - Atlanta, GA (2014)
  • "Bronchitis and Bronchiectasis" UBMD Primary Care Update; UBMD (2014)
  • "Physician Grand Rounds" North American Cystic Fibrosis Conference; Cystic Fibrosis Foundation (2013)
  • "Solitary Pulmonary Nodule" Internal Medicine Pediatrics Conference (2013)
  • "Cystic Fibrosis" Pulmonary Faculty and Fellow Conference (2012)
  • "Assessing Parent Readiness for Transition from a Pediatric to an Adult CF Program" North American Cystic Fibrosis Conference - Orlando, FL (2012)
  • "Cystic Fibrosis" Pulmonary Faculty and Fellow Conference (2010)
See all (11 more)

Service Activities:

  • CFF Peer Mentoring Champion; Member (2017–present)
  • ATS Transition Consortium Co-Chair; Co-Chair (2016–present)
  • CF Expert Panel Co-Chair; Co-Chair (2016–present)
  • Cystic Fibrosis Foundation; Success With Research Therapies Consortium;; Grant Reviewer (2015–present)
  • Partnerships for Sustaining Daily Care Communications Intitiative National CFF; Member (2015–present)
  • Adult Guide - Online Cystic Fibrosis Resource www.cff.org/adults Adults with CF can seek information from an accredited website with helpful resources regarding different topics related to life as an adult with CF.; Editor (2012–present)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

UBMD - CF Center of WNY
Cystic Fibrosis Therapeutics Development Center of WNY
Conventus Outpatient Building
1001 Main Street, 4th & 5th floors
Buffalo, NY 14203
(716) 323-0110

Buffalo General Hospital
Department of Pulmonary Medicine
100 High St. B-8
(716) 859-2271
Buffalo, New York 14203
Phone: (716) 323-0110/859-2271
ckinyon@buffalo.edu

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD